Chlorotoxin binds to both matrix metalloproteinase 2 and neuropilin 1.

annexin chlorotoxin enzyme inhibitor flow cytometry glioblastoma matrix metalloproteinase neuropilin protein targeting protein–protein interaction vascular endothelial growth factor

Journal

The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R

Informations de publication

Date de publication:
09 2023
Historique:
received: 16 02 2023
revised: 03 06 2023
accepted: 28 06 2023
medline: 2 10 2023
pubmed: 3 7 2023
entrez: 2 7 2023
Statut: ppublish

Résumé

Chlorotoxin (CTX), a scorpion venom-derived 36-residue miniprotein, binds to and is taken up selectively by glioblastoma cells. Previous studies provided controversial results concerning target protein(s) of CTX. These included CLC3 chloride channel, matrix metalloproteinase 2 (MMP-2), regulators of MMP-2, annexin A2, and neuropilin 1 (NRP1). The present study aimed at clarifying which of the proposed binding partners can really interact with CTX using biochemical methods and recombinant proteins. For this purpose, we established two new binding assays based on anchoring the tested proteins to microbeads and quantifying the binding of CTX by flow cytometry. Screening of His-tagged proteins anchored to cobalt-coated beads indicated strong interaction of CTX with MMP-2 and NRP1, whereas binding to annexin A2 was not confirmed. Similar results were obtained with fluorophore-labeled CTX and CTX-displaying phages. Affinity of CTX to MMP-2 and NRP1 was assessed by the "immunoglobulin-coated bead" test, in which the proteins were anchored to beads by specific antibodies. This assay yielded highly reproducible data using both direct titration and displacement approach. The affinities of labeled and unlabeled CTX appeared to be similar for both MMP-2 and NRP1 with estimated K

Identifiants

pubmed: 37394009
pii: S0021-9258(23)02026-4
doi: 10.1016/j.jbc.2023.104998
pmc: PMC10477481
pii:
doi:

Substances chimiques

Chlorotoxin 06UV5RFW57
Matrix Metalloproteinase 2 EC 3.4.24.24
Neuropilin-1 144713-63-3
Scorpion Venoms 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104998

Informations de copyright

Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.

Auteurs

Sándor Farkas (S)

VRG Therapeutics Ltd, Budapest, Hungary. Electronic address: sandor.farkas@vrgtherapeutics.com.

Daniel Cioca (D)

VRG Therapeutics Ltd, Budapest, Hungary.

József Murányi (J)

VRG Therapeutics Ltd, Budapest, Hungary.

Péter Hornyák (P)

VRG Therapeutics Ltd, Budapest, Hungary.

Attila Brunyánszki (A)

VRG Therapeutics Ltd, Budapest, Hungary.

Patrik Szekér (P)

VRG Therapeutics Ltd, Budapest, Hungary.

Eszter Boros (E)

Department of Biochemistry, ELTE Eötvös Loránd University, Budapest, Hungary.

Patrik Horváth (P)

Department of Biochemistry, ELTE Eötvös Loránd University, Budapest, Hungary.

Zoltán Hujber (Z)

VRG Therapeutics Ltd, Budapest, Hungary.

Gábor Z Rácz (GZ)

VRG Therapeutics Ltd, Budapest, Hungary.

Noémi Nagy (N)

VRG Therapeutics Ltd, Budapest, Hungary.

Rebeka Tóth (R)

VRG Therapeutics Ltd, Budapest, Hungary.

László Nyitray (L)

Department of Biochemistry, ELTE Eötvös Loránd University, Budapest, Hungary.

Zalán Péterfi (Z)

VRG Therapeutics Ltd, Budapest, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH